Topic: Onyx Pharmaceuticals Inc.

Phase III Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival

Drugs.com - 602 days ago
Berlin, June 14, 2010 - Bayer HealthCare and Onyx Pharmaceuticals today announced that the final analysis of the Phase III NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating Nexavar? (sorafenib) tablets in patients with advanced non-squamous, non-small cell lung cancer (NSCLC) showed ...